Status:
TERMINATED
Erenumab For Treatment of Hemicrania Continua
Lead Sponsor:
Mayo Clinic
Conditions:
Hemicrania Continua
Eligibility:
All Genders
18-66 years
Phase:
PHASE2
Brief Summary
This research is being conducting to learn if the study drug erenumab is successful in treating hemicrania continua. The study is also evaluating the safety and tolerability of erenumab in individuals...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Adults over the age of 18-66
- At least a 12 month history of hemicrania continua (unremitting subtype) according to International Classification of Headache Disorders, 3rd Edition (ICHD-3)1
- Previous or current complete response to indomethacin
- Stable preventive treatment for at least 2 months and no anticipated need to adjust/add current headache prevention treatment
- Exclusion Criteria
- Nonresponse to a therapeutic dose of indomethacin for hemicrania continua when used for at least 1 week
- Pregnant or lactating subjects
- Use of barbiturate or opioid \>6 days per month; history of chronic migraine
- History of previous trigeminal-autonomic cephalalgia
- History within previous 2 months of interventional procedure for headache (occipital or other extracranial nerve block, sphenopalatine ganglion block, cervical facet block, facet rhizotomy)
- History of cranial nerve/rhizolysis
- Botulinumtoxin injection with previous 4 months
- Parenteral infusion of or oral corticosteroid use for more than 3 days within 4 weeks prior to screening phase
Exclusion
Key Trial Info
Start Date :
August 4 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 6 2022
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT04303845
Start Date
August 4 2021
End Date
April 6 2022
Last Update
February 17 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Arizona
Scottsdale, Arizona, United States, 85259